CYTH
- Cyclo Therapeutics, Inc.
()
Overview
Company Summary
Cyclo Therapeutics, Inc. (CYTH) is a biotechnology company that is focused on developing innovative treatments for rare and devastating diseases. They utilize a proprietary platform technology known as Trappsol� to develop novel therapies that target the underlying causes of these diseases.
The company primarily focuses on developing cyclodextrin-based therapies, which are specially designed molecules capable of encapsulating and removing harmful substances from cells. Cyclo Therapeutics applies this technology to develop treatments for rare diseases categorized as lysosomal storage disorders (LSDs) and other neurological conditions.
Lysosomal storage disorders are genetic conditions that result from the deficiency of specific enzymes responsible for breaking down waste materials within cells. This leads to the accumulation of these waste materials, causing damage to various organs and systems. Cyclo Therapeutics aims to address these disorders by using cyclodextrins to remove the accumulated waste substances and restore normal cellular function.
Cyclo Therapeutics' lead investigational drug is Trappsol� Cyclo�, which is currently being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C (NPC). NPC is a rare and progressive genetic disorder that affects multiple organs and systems, particularly the central nervous system. By employing Trappsol� Cyclo�, Cyclo Therapeutics aims to provide a potential treatment option for individuals suffering from NPC, addressing the underlying disease process and potentially improving the quality of life for patients.
In addition to NPC, Cyclo Therapeutics is exploring the potential of cyclodextrins in treating other LSDs and neurological conditions with unmet medical needs. Their research and development efforts involve collaborating with academic institutions, medical centers, and other organizations in order to advance their scientific knowledge and expand their therapeutic pipeline.
Overall, Cyclo Therapeutics, Inc. is dedicated to developing cutting-edge therapies using cyclodextrins to provide hope and improved outcomes for patients suffering from rare and devastating diseases.